New Risk • Jul 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (30% accrual ratio). Minor Risk Market cap is less than US$100m (UK£13.7m market cap, or US$18.3m). New Risk • May 22
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£145k Forecast net loss in 1 year: UK£0 This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£0 net loss next year). Share price has been volatile over the past 3 months (9.7% average weekly change). Market cap is less than US$100m (UK£13.0m market cap, or US$17.5m). New Risk • May 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£499k net loss next year). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (UK£14.9m market cap, or US$20.3m). Buy Or Sell Opportunity • Mar 17
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 17% to UK£0.14. The fair value is estimated to be UK£0.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 17% in a year. Earnings are forecast to decline by 243% in the next year. New Risk • Feb 15
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£145k Forecast net loss in 1 year: UK£499k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£499k net loss next year). Market cap is less than US$100m (UK£8.84m market cap, or US$12.1m). Announcement • Jan 30
RUA Life Sciences plc, Annual General Meeting, Mar 17, 2026 RUA Life Sciences plc, Annual General Meeting, Mar 17, 2026. Location: gailes hotel, marine drive, irvine, ayrshire ka11 5ae, United Kingdom New Risk • Jan 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 60% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (UK£8.69m market cap, or US$11.6m). Reported Earnings • Jun 25
Full year 2025 earnings released: EPS: UK£0 (vs UK£0.043 loss in FY 2024) Full year 2025 results: EPS: UK£0 (improved from UK£0.043 loss in FY 2024). Revenue: UK£4.11m (up 88% from FY 2024). Net income: UK£1.0k (up UK£1.44m from FY 2024). Profit margin: 0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. New Risk • Apr 28
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 44% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 44% per year for the foreseeable future. High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (UK£7.21m market cap, or US$9.62m). Minor Risk Revenue is less than US$5m (UK£2.9m revenue, or US$3.9m). Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Director Lachlan Smith was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Dec 12
First half 2025 earnings released: EPS: UK£0.01 (vs UK£0.046 loss in 1H 2024) First half 2025 results: EPS: UK£0.01 (up from UK£0.046 loss in 1H 2024). Revenue: UK£1.52m (up 92% from 1H 2024). Net income: UK£636.0k (up UK£1.65m from 1H 2024). Profit margin: 42% (up from net loss in 1H 2024). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Announcement • Sep 10
RUA Life Sciences plc (AIM:RUA) acquired Analytic Biosurgical Solutions from IPSA Group for €0.08 million. RUA Life Sciences plc (AIM:RUA) acquired Analytic Biosurgical Solutions from IPSA Group for €0.08 million on September 9, 2024. The gross assets of Abiss at December 31, 2023 were €2.265 million. Revenue in the year to December 31, 2023 was €2.159 million. Loss before tax was €0.352 million after depreciation and amortization charges of €0.537 million. In the year to December 31, 2023, Abiss had net positive cash flow of €0.223 million and cash balances of €0.279 million at the year end. Net Assets/Shareholders Funds at December 31, 2023 were €1.624 million. Non-current liabilities totaled €0.64 million at December 31, 2023. Giles Balleny, Dan Hodkinson, Charlie Combe, Michael Johnson of Cavendish Capital Markets Limited acted as financial advisor to RUA Life Sciences plc.
RUA Life Sciences plc (AIM:RUA) completed the acquisition of Analytic Biosurgical Solutions from IPSA Group on September 9, 2024. Reported Earnings • Jul 25
Full year 2024 earnings released: UK£0.043 loss per share (vs UK£0.09 loss in FY 2023) Full year 2024 results: UK£0.043 loss per share (improved from UK£0.09 loss in FY 2023). Revenue: UK£2.19m (flat on FY 2023). Net loss: UK£1.44m (loss narrowed 28% from FY 2023). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 6.4% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings. Announcement • Jul 25
RUA Life Sciences plc, Annual General Meeting, Aug 27, 2024 RUA Life Sciences plc, Annual General Meeting, Aug 27, 2024. Location: gailes hotel, marine drive, irvine, ayrshire ka11 5ae, United Kingdom New Risk • Jul 15
New major risk - Revenue and earnings growth Earnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (180% increase in shares outstanding). Market cap is less than US$10m (UK£6.75m market cap, or US$8.76m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (UK£1.9m revenue, or US$2.4m). New Risk • Jul 05
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (180% increase in shares outstanding). Market cap is less than US$10m (UK£6.83m market cap, or US$8.73m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (UK£277k net loss in 2 years). Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (UK£1.9m revenue, or US$2.4m). New Risk • May 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (180% increase in shares outstanding). Market cap is less than US$10m (UK£7.60m market cap, or US$9.70m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£277k net loss in 2 years). Revenue is less than US$5m (UK£1.9m revenue, or US$2.4m). Announcement • Apr 05
RUA Life Sciences plc Provides Revenue Guidance for the Year Ended 31 March 2024 RUA Life Sciences plc provided revenue guidance for the year ended 31 March 2024. The first half of the financial year was impacted by operational issues, resulting in the delayed shipment of products from the Contract Manufacturing business. As anticipated, the revenue shortfall experienced during first half has been fully compensated by a strong second half performance. As a result, the Company expects to report, subject to audit, fiscal year 2024 revenue of £2.2 million, which is in line with market expectations. Announcement • Dec 20
Rua Life Sciences plc Provides an Update on Recent Developments of the Rua Leaflet Composite RUA Life Sciences provided an update on recent developments of the RUA leaflet composite. The objective for RUA Structural Heart during 2023 was to evaluate heart valve leaflet material and compare the performance of 100% polymeric valves with the novel composite developed by the Group. The computational modelling of the composite material at the design stage suggested that its mechanical properties would be ideal for heart valve leaflets. Testing undertaken by RUA has demonstrated: Flex fatigue stability over 400m cycles Durability as a heart valve leaflet over 200m cycles; Rem remarkable tensile strength properties exceeding both base fabric and polymer; Similar tensile strength in multiple directions; Highly flexible allowing improved valve efficiency; Narrow crimping profile allowing TAVR benefits; Retention of ElastEon blood contacting properties such as calcification and thrombogenicity; Material very stable with no delamination during testing and high tear resistance. Patient protection for the material has now been sought and coupled with the testing results achieved; RUA is now seeking to commercialise the RUA composite material as an alternative to animal tissue used in the manufacture of heart valves. Engagement with the industry has been positive and, as previously announced, a major heart valve company has approached the Company to undertake its own tests and has now entered into a material testing agreement (MTA) in order to do so. While there can be no certainty that the parties will progress to an agreement, an MTA is the preliminary step to further collaboration. New Risk • Dec 20
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 180% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (180% increase in shares outstanding). Market cap is less than US$10m (UK£6.36m market cap, or US$8.05m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£277k net loss in 2 years). Revenue is less than US$5m (UK£1.9m revenue, or US$2.4m). New Risk • Dec 19
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: UK£1.9m Forecast net loss in 2 years: UK£277k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Market cap is less than US$10m (UK£2.47m market cap, or US$3.13m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£277k net loss in 2 years). Revenue is less than US$5m (UK£1.9m revenue, or US$2.4m). Announcement • Dec 08
RUA Life Sciences plc has completed a Follow-on Equity Offering in the amount of £4.386302 million. RUA Life Sciences plc has completed a Follow-on Equity Offering in the amount of £4.386302 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 36,363,636
Price\Range: £0.11
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 727,272
Price\Range: £0.11
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,784,566
Price\Range: £0.11
Transaction Features: Regulation S; Subsequent Direct Listing Price Target Changed • Dec 07
Price target decreased by 48% to UK£2.84 Down from UK£5.45, the current price target is an average from 2 analysts. New target price is 2,443% above last closing price of UK£0.11. Stock is down 66% over the past year. The company is forecast to post a net loss per share of UK£0.059 next year compared to a net loss per share of UK£0.09 last year. Announcement • Dec 01
RUA Life Sciences plc has filed a Follow-on Equity Offering in the amount of £4.83 million. RUA Life Sciences plc has filed a Follow-on Equity Offering in the amount of £4.83 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 36,363,636
Price\Range: £0.11
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 727,272
Price\Range: £0.11
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,818,181
Price\Range: £0.11
Transaction Features: Regulation S; Subsequent Direct Listing Board Change • Sep 08
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Ian Ardill was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 01
RUA Life Sciences plc Announces Iain Anthony, Director of Clinical and Regulatory Affairs Tenders His Resignation RUA Life Sciences plc announced that Iain Anthony, Director of Clinical and Regulatory Affairs has tendered his resignation from the Company in order to accept an opportunity elsewhere within the industry. Iain joined RUA in November 2021 and has overseen the building of the Regulatory and Quality teams together with further development of the vascular graft device and was instrumental in undertaking the Q-Sub process with the FDA which has recently concluded succesfully. Iain will step down from the board with immediate effect but will continue in his role as an employee for an appropriate handover period while the Board looks for his successor. Reported Earnings • Dec 12
First half 2023 earnings released: UK£0.051 loss per share (vs UK£0.059 loss in 1H 2022) First half 2023 results: UK£0.051 loss per share (improved from UK£0.059 loss in 1H 2022). Revenue: UK£1.10m (up 56% from 1H 2022). Net loss: UK£1.14m (loss narrowed 13% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 26% per year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Ian Ardill was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 11
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: UK£0.093 loss per share (down from UK£0.082 loss in FY 2021). Revenue: UK£1.63m (up 6.3% from FY 2021). Net loss: UK£2.07m (loss widened 43% from FY 2021). Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) exceeded analyst estimates by 24%. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Ian Ardill was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 21
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Ian Ardill was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Dec 17
First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First half 2022 results: UK£0.059 loss per share (down from UK£0.038 loss in 1H 2021). Revenue: UK£708.0k (up 12% from 1H 2021). Net loss: UK£1.31m (loss widened 115% from 1H 2021). Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) missed analyst estimates by 18%. Earnings per share (EPS) missed analyst estimates by 18%. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Board Change • Sep 13
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Ian Ardill was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 10
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Ian Ardill was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Jul 19
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from UK£1.89m to UK£1.95m. Forecast EPS reduced from -UK£0.087 to -UK£0.11 per share. Medical Equipment industry in the United Kingdom expected to see average net income decline 2.6% next year. Consensus price target broadly unchanged at UK£5.25. Share price rose 5.8% to UK£1.36 over the past week. Reported Earnings • Jul 12
Full year 2021 earnings released: UK£0.082 loss per share (vs UK£0.056 loss in FY 2020) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: UK£1.53m (up 204% from FY 2020). Net loss: UK£1.45m (loss widened 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Reported Earnings • Dec 14
First half 2021 earnings released: UK£0.038 loss per share The company reported a decent first half result with improved revenues, although control over expenses were weaker and an increased loss. First half 2021 results: Revenue: UK£631.0k (up 111% from 1H 2020). Net loss: UK£609.0k (loss widened 285% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 67% per year but the company’s share price has increased by 50% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Nov 24
New 90-day high: UK£1.53 The company is up 27% from its price of UK£1.20 on 26 August 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 
